Cerium Pharmaceuticals

Executive Summary

Cerium Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for kidney diseases. Its lead candidate, a synthetic form of adrenocorticotropic hormone (ACTH), is being developed for primary membranous nephropathy (PMN), a rare autoimmune kidney disease with no FDA-approved therapies. The company has advanced this candidate to Phase 3 clinical trials, positioning itself as a potential first-to-market option for PMN patients. With a focused pipeline and a clear unmet medical need, Cerium aims to address a significant gap in nephrology care.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data readout for synthetic ACTH in PMN70% success
• Q2 2027FDA pre-NDA meeting or breakthrough therapy designation60% success
• Q3 2026Strategic partnership or licensing deal for commercial rights50% success